Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Return on Capital Employed of 32.79% for Q3 2025, down 882.0% year-over-year from 4.19% in Q3 2024, and up 19.94% quarter-over-quarter from 40.95% in Q2 2025.
Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 32.79% for Q3 2025.
- In Q3 2025, Return on Capital Employed fell 882.0% year-over-year to 32.79%; the TTM figure through Sep 2025 stood at 32.79% (down 882.0% YoY), while the FY2024 annual figure was 39.44%, up 16.0% from the prior year.
- Return on Capital Employed for Q3 2025 stood at 32.79%, up from 40.95% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.8% in Q2 2024, with the low at 57.85% in Q1 2023.
- The 5-year median for Return on Capital Employed is 39.89% (2021), against an average of 38.67%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 3640 bps in 2024, then tumbled 2215 bps in 2025.
- Dianthus Therapeutics' Return on Capital Employed stood at 39.89% in 2021, then slumped by 32 bps to 52.75% in 2022, then surged by 48 bps to 27.32% in 2023, then slipped by 8 bps to 29.47% in 2024, then fell by 11 bps to 32.79% in 2025.
- Business Quant data shows DNTH's Return on Capital Employed at 32.79% in Q3 2025, 40.95% in Q2 2025, and 34.04% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -32.79% |
| Jun 30, 2025 | -40.95% |
| Mar 31, 2025 | -34.04% |
| Dec 31, 2024 | -29.47% |
| Sep 30, 2024 | -23.97% |
| Jun 30, 2024 | -18.80% |
| Mar 31, 2024 | -21.45% |
| Dec 31, 2023 | -27.32% |
| Sep 30, 2023 | -37.49% |
| Jun 30, 2023 | -49.87% |
| Mar 31, 2023 | -57.85% |
| Dec 31, 2022 | -52.75% |
| Sep 30, 2022 | -44.87% |
| Jun 30, 2022 | -46.28% |
| Mar 31, 2022 | -44.83% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -36.24% |
| Jun 30, 2021 | -43.03% |
| Mar 31, 2021 | -52.92% |
| Dec 31, 2020 | -50.22% |